CONTINUED
THERAPY
Continued Disease
Activity
CONTINUED
THERAPY
of Synovitis
Active Systemic Features
Degrees of Synovitis
Abatacept (B)
Anakinra (B)
TNF-α inhibitor (C)
Tocilizumab (B)
Anakinra
MTX or
leflunomide
Anakinra
MTX or
leflunomide
AJC >0
Disease activity
following 1 month
of anakinra
AJC >0
Disease activity
following 3 months
of MTX or
leflunomide
AJC >0
Disease activity
following 1 month
of anakinra
AJC >0
Disease activity
following 3 months
of MTX or
leflunomide
Abatacept (D)
MTX or leflunomide (D)
TNF-α inhibitor (D)
Tocilizumab (B)
Abatacept (B)
Anakinra (B)
TNF-α inhibitor (C)
Tocilizumab (B)
Abatacept (D)
MTX or leflunomide (D)
TNF-α inhibitor (D)
Tocilizumab (B)
Abatacept (B)
Anakinra (B)
TNF-α inhibitor (C)
Tocilizumab (B)
B
C
C
C
C
B
